<DOC>
	<DOCNO>NCT01020175</DOCNO>
	<brief_summary>350 patient early leukemia assign receive peripheral blood bone marrow transplantation ; occurrence acute chronic graft versus host disease , survival , transplantation-related mortality , relapse rate compare .</brief_summary>
	<brief_title>Peripheral Blood ( PB ) Versus Bone Marrow ( BM ) Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>The trial design investigate safety outcome allogeneic filgrastim-mobilized PBPCT compare allogeneic BMT patient standard-risk leukemia . A total 350 patient 18 55 year age acute leukemias remission chronic myelogenous leukemia first chronic phase randomize receive either filgrastim-mobilized peripheral blood progenitor cell bone marrow cell HLA-identical sibling donor standard high-dose chemoradiotherapy . The study approve ethic committee participate center , patient donor give inform consent study-related procedure perform . Donor-recipient pair randomize undergo either BMT PBPCT . Randomization carry centrally International Institute Drug Development ( id2 ) , Brussels , Belgium , use minimization method allocate donor recipient allogeneic BMT PBPCT . The randomization stratum follow : diagnosis ( chronic myeloid leukemia [ CML ] v disease ) , sex mismatch donor recipient , whether donor female nulliparous . Follow-up visit schedule 6 , 12 , 24 , 36 month date transplantation . Neutrophil platelet recovery occur significantly fast transplantation peripheral blood progenitor cell bone marrow transplantation . Acute graft versus host disease grade II-IV significantly frequent recipient peripheral blood progenitor cell recipient marrow cell The cumulative incidence chronic graft versus host disease high peripheral blood progenitor cell bone marrow cell</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients either diagnosis AML first second remission , first untreated relapse ( blast count marrow &lt; 30 % ) ; ALL first second remission , first untreated relapse ( blast count marrow &lt; 30 % ) ; CML first chronic phase , first accelerate phase ( total blast promyelocytes marrow peripheral blood &lt; 30 % ) MDS ( exclude RAEBt ) . Age 18 55 year . ECOG performance status 0,1 2 . HLAidentical sibling donor . Written informed consent . Serum creatinine 10 % normal range centre . Left ventricular size function abnormal . DLCO &lt; 50 % . Bilirubin &gt; 2mg/dL ( 34.2 Âµmol/L ) . Splenectomised splenic irradiation . Psychiatric , addictive , disorder , compromise ability give truly informed consent participation study . Currently receive nonlicensed drug may affect GVHD engraftment . Pregnant lactating woman . Known sensitivity E.coli derive product . HIV positive . Previously receive BM/PBPC transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>allogeneic transplantation</keyword>
	<keyword>Leukemia</keyword>
	<keyword>GvHD</keyword>
	<keyword>MDS</keyword>
</DOC>